Recent Updates
Recently added Catalysts

HSV vaccine or SB208141, GSK Biologicals' glycoprotein D-Alum/3-deacylated form of Monophosphoryl Lipid A candidate genital herpes vaccine

Phase 3

Herpes Simplex Infection | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Aug 27, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment8,323

FDA Designations

No designations recorded

Clinical trial landscape

HSV vaccine or SB208141, GSK Biologicals' glycoprotein D-Alum/3-deacylated form of Monophosphoryl Lipid A candidate genital herpes vaccine · 1 trial · 1 indication

Phase 3 1
NCT00057330HerpeVac Trial for Young WomenHerpes Simplex Infection
COMPLETED8,323 Analytics
PHASE3COMPLETED
HerpeVac Trial for Young Women
Herpes Simplex InfectionUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2
Between Months 2 and 20

Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.

Secondary Endpoints

Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2
Between Months 7 and 20
Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion.
Between Months 2 and 20
Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion
Between Months 7 and 20
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Herpes Simplex Virus GroupEXPERIMENTALFemales between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
Havrix GroupEXPERIMENTALFemales between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.

Interventions

NameTypeDescription
HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccineBIOLOGICALthe vaccine was administered intramuscularly in the non-dominant deltoid
Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccineBIOLOGICALthe vaccine was administered intramuscularly in the non-dominant deltoid
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 30 Years
SexFEMALE
Healthy VolunteersYes
Study Sites75

Inclusion Criteria: * A female between, and including, 18 and 30 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Se...

Countries:United StatesCanada
Unlock Eligibility Criteria